214 related articles for article (PubMed ID: 12958065)
1. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
2. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
[TBL] [Abstract][Full Text] [Related]
3. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
4. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
5. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
Front Immunol; 2018; 9():1251. PubMed ID: 29951051
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
9. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
Panch SR; Guo L; Vassallo R
Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
[TBL] [Abstract][Full Text] [Related]
10. Platelet refractoriness and alloimmunization.
Slichter SJ
Leukemia; 1998 Sep; 12 Suppl 1():S51-3. PubMed ID: 9777897
[TBL] [Abstract][Full Text] [Related]
11. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.
Slichter SJ; Bolgiano D; Kao KJ; Kickler TS; McFarland J; McCullough J; Woodson R
Transfus Med Rev; 2011 Apr; 25(2):102-10. PubMed ID: 21345638
[TBL] [Abstract][Full Text] [Related]
12. Prestorage leukocyte depletion is not necessarily required for the prevention of refractoriness to platelet transfusion.
de Wolf J; Westerterp A; Smit Sibinga C; Halie MR
Blood; 1995 Oct; 86(8):3263-4. PubMed ID: 7579424
[No Abstract] [Full Text] [Related]
13. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
[TBL] [Abstract][Full Text] [Related]
14. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
16. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
17. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
[TBL] [Abstract][Full Text] [Related]
18. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
19. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
20. [Refractory effect and alloimmunization after transfusion of thrombocytes].
Volkova RI; Agranenko VA
Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]